High population immunity from prior infections and updated vaccines has kept SARS-CoV-2 evolution within the Omicron lineage, with current subvariants such as XFG.1.1 circulating at low levels and producing no widespread surges in hospitalizations. The World Health Organization has not designated any new variant of concern since JN.1 in late 2023, reflecting the elevated bar for that classification—requiring clear evidence of substantially increased transmissibility, severity, or immune escape that meaningfully affects public health. Recent monitoring of the highly mutated BA.3.2 lineage shows modest spread in parts of Europe and limited U.S. detections without triggering emergency thresholds or exponential growth. Ongoing genomic surveillance and stable epidemiological indicators reinforce trader consensus that a new designation remains improbable through the end of 2026.